Tempus’s technology seeks to personalise laboratory testing by analysing results in the context of a patient’s other clinical information.
I’ve been nibbling at Tempus shares in my ‘YOLO’ pot since the IPO last month.
It’s an interesting company, which seeks to leverage data in health.
Tempus was set up by the founder of Groupon after his wife was diagnosed with breast cancer.
The company’s backers include Google and Baillie Gifford. It’s a highly speculative play though.
So far, so good – touch wood.
I’m up 50% in the past month on Tempus though it could have gone the other way and may yet.
There’s a fair bit of short interest which is always unnerving, especially as it’s swept up in something of an anything-AI bubble.
But I think TEM has big potential and, even if it goes belly up, it’s a relatively small position.
As a cancer patient myself, I’m excited about just how much good this company could do.
2 Likes